To that end, the authors initially compared the gene expression profiles of doxorubicin-exposed versus untreated lymphomas, specifically senescence-competent primary Eμ-Myc transgenic Bcl2-overexpressing lymphomas (dubbed as Eμ-Myc;Bcl2) and senescence-incompetent Suv39h1-deficient Eμ-Myc;Bcl2 lymphomas. The gene discussed is SUV39H1; the disease is lymphoma.